NebuFlow is developing next-generation nebulizers that utilize advanced aerosol delivery technology to enhance the administration of respiratory treatments. This innovation addresses the challenge of inefficient drug delivery in traditional nebulizers, improving patient outcomes and treatment adherence.
Funding
$8.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional nebulizers often suffer from inefficient drug delivery, leading to suboptimal treatment outcomes and reduced patient adherence in respiratory therapies. The limitations of conventional aerosolization technologies hinder effective medication deposition in the lungs.
Solution
NebuFlow is engineering next-generation nebulizers employing advanced aerosol delivery technology to improve respiratory treatment administration. Their innovative devices enhance drug delivery efficiency, ensuring more medication reaches the targeted areas within the respiratory system. By optimizing aerosol particle size and distribution, NebuFlow's nebulizers aim to maximize therapeutic effects while minimizing drug wastage. This technology seeks to improve patient outcomes by providing more effective and consistent respiratory treatments.
Target Audience
The primary target audience includes patients with respiratory conditions such as asthma, COPD, and cystic fibrosis, as well as healthcare providers and pharmaceutical companies involved in respiratory therapy.
Features
- Advanced aerosol delivery technology for optimized drug deposition.
- Improved efficiency in medication delivery compared to traditional nebulizers.
- Enhanced particle size control for targeted respiratory treatment.